BR112012003511A2 - agente para o tratamento ou prevenção de osteoporose, preparação de combinação ou kit de tratamento, e, agente para a inibição ou prevenção de fraturas ósseas - Google Patents

agente para o tratamento ou prevenção de osteoporose, preparação de combinação ou kit de tratamento, e, agente para a inibição ou prevenção de fraturas ósseas

Info

Publication number
BR112012003511A2
BR112012003511A2 BR112012003511A BR112012003511A BR112012003511A2 BR 112012003511 A2 BR112012003511 A2 BR 112012003511A2 BR 112012003511 A BR112012003511 A BR 112012003511A BR 112012003511 A BR112012003511 A BR 112012003511A BR 112012003511 A2 BR112012003511 A2 BR 112012003511A2
Authority
BR
Brazil
Prior art keywords
agent
preventing
inhibiting
treating
bone fractures
Prior art date
Application number
BR112012003511A
Other languages
English (en)
Portuguese (pt)
Inventor
Kato Hiroki
Hori Kazuyoshi
Serada Masahi
Kobayashi Nobuyuki
Shirae Shinichiro
Kuroda Tatsuhiko
Nozaki Yoshihide
Masunaga Yuko
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43732444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012003511(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of BR112012003511A2 publication Critical patent/BR112012003511A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112012003511A 2009-09-09 2010-09-08 agente para o tratamento ou prevenção de osteoporose, preparação de combinação ou kit de tratamento, e, agente para a inibição ou prevenção de fraturas ósseas BR112012003511A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009208039 2009-09-09
PCT/JP2010/065379 WO2011030774A1 (ja) 2009-09-09 2010-09-08 １回当たり１００～２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤

Publications (1)

Publication Number Publication Date
BR112012003511A2 true BR112012003511A2 (pt) 2019-09-24

Family

ID=43732444

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012003511A BR112012003511A2 (pt) 2009-09-09 2010-09-08 agente para o tratamento ou prevenção de osteoporose, preparação de combinação ou kit de tratamento, e, agente para a inibição ou prevenção de fraturas ósseas

Country Status (16)

Country Link
US (3) US20120252729A1 (https=)
EP (3) EP2476429B1 (https=)
JP (13) JPWO2011030774A1 (https=)
KR (8) KR20190095552A (https=)
CN (2) CN102470164B (https=)
AU (1) AU2010293488B2 (https=)
BR (1) BR112012003511A2 (https=)
CA (1) CA2772656A1 (https=)
ES (3) ES2663322T3 (https=)
IL (1) IL217854A (https=)
IN (1) IN2012DN00857A (https=)
MX (1) MX335951B (https=)
NZ (2) NZ598370A (https=)
RU (1) RU2564894C2 (https=)
WO (1) WO2011030774A1 (https=)
ZA (1) ZA201201720B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101686271B1 (ko) * 2009-11-18 2016-12-13 아사히 가세이 파마 가부시키가이샤 인간 변형성 슬관절증의 예방제 및/또는 치료제 및/또는 악화 억제제
JP6235219B2 (ja) * 2013-03-21 2017-11-22 旭化成ファーマ株式会社 脊椎椎体間固定術後の骨癒合促進剤
US10394953B2 (en) 2015-07-17 2019-08-27 Facebook, Inc. Meme detection in digital chatter analysis
US20190381341A1 (en) * 2017-02-01 2019-12-19 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
CA3075984C (en) * 2017-09-22 2024-10-01 Asahi Kasei Pharma Corporation LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TERIPARATIDE WITH EXCELLENT PHARMACOKINETIC AND/OR SAFETY PROPERTIES
ES3009869T3 (en) 2018-10-29 2025-03-31 Asahi Kasei Pharma Corp An improved teriparatide dosage regimen for use in preventing or treating osteoporosis characterized by administering teriparatide or salt thereof twice a week
KR102920552B1 (ko) * 2024-01-03 2026-01-30 김도영 나노입자경의 탄산칼슘과 탄산마그네슘 제조방법 및 그 방법으로 제조된 골다공증 예방치료제

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2505812B2 (ja) 1987-07-10 1996-06-12 旭化成工業株式会社 ｈ―ＰＴＨ（１―３４）凍結乾燥組成物
JP2662842B2 (ja) 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
JPH0873376A (ja) 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
ZA9811127B (en) * 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
NZ523457A (en) 2000-06-30 2004-11-26 Daiichi Suntory Pharma Co Composition for stimulating bone formation comprising hPTH in which the acetic acid component is low enough for administration to the nasal mucosa
JP5042419B2 (ja) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 骨形成促進剤および骨形成促進組成物
JP4931306B2 (ja) 2001-09-27 2012-05-16 旭化成ファーマ株式会社 骨形成を安全に促進させる医薬複合剤
CN1816324A (zh) * 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
WO2005102381A1 (ja) * 2004-04-26 2005-11-03 Ono Pharmaceutical Co., Ltd. カテプシンｋ阻害薬およびpth類を併用することを特徴とする骨密度増加剤
CA2567056A1 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
JP2006241098A (ja) * 2005-03-04 2006-09-14 Univ Kurume 骨量減少症の予防または治療薬
ES2443581T3 (es) * 2006-02-09 2014-02-19 Biomimetic Therapeutics, Llc Composiciones y métodos para el tratamiento de hueso
DE102006043846A1 (de) * 2006-03-14 2007-09-20 Claudia Zours Wirbelsäulenorthesen
AU2007225056A1 (en) * 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
CN101274961A (zh) * 2006-03-30 2008-10-01 天津医科大学 重组人甲状旁腺素相关蛋白
CN101125201A (zh) * 2006-08-17 2008-02-20 石家庄欧意药业有限公司 治疗骨质疏松症或防治由于骨质疏松而导致的骨折的药物组合物及其应用
CN101307105B (zh) * 2008-04-28 2012-08-29 中国药科大学 一种能串联表达和同步酸水解释放的人甲状旁腺素1-34肽类似物及其制备方法和应用

Also Published As

Publication number Publication date
JP6301524B2 (ja) 2018-03-28
JP2015157854A (ja) 2015-09-03
KR20170089018A (ko) 2017-08-02
JP6043008B2 (ja) 2016-12-14
JP2017105863A (ja) 2017-06-15
JP6150846B2 (ja) 2017-06-21
KR20140130754A (ko) 2014-11-11
NZ598370A (en) 2014-04-30
AU2010293488A1 (en) 2012-03-29
KR20210040171A (ko) 2021-04-12
US20140357560A1 (en) 2014-12-04
CA2772656A1 (en) 2011-03-17
RU2564894C2 (ru) 2015-10-10
EP2476429B1 (en) 2018-03-07
KR20170089017A (ko) 2017-08-02
US20140249084A1 (en) 2014-09-04
WO2011030774A1 (ja) 2011-03-17
KR20190095552A (ko) 2019-08-14
KR102335703B1 (ko) 2021-12-07
EP2682125B1 (en) 2020-11-04
RU2012108635A (ru) 2013-10-20
JP2015147813A (ja) 2015-08-20
JP6198346B2 (ja) 2017-09-20
JP2017105862A (ja) 2017-06-15
EP2476429A1 (en) 2012-07-18
ES2662018T3 (es) 2018-04-05
EP2682125A1 (en) 2014-01-08
JP2017105859A (ja) 2017-06-15
ES2843649T3 (es) 2021-07-20
CN102470164A (zh) 2012-05-23
KR102424644B1 (ko) 2022-07-25
EP2682124B1 (en) 2018-02-28
IN2012DN00857A (https=) 2015-07-10
JP2017105861A (ja) 2017-06-15
EP2682124A1 (en) 2014-01-08
ZA201201720B (en) 2012-11-28
JPWO2011030774A1 (ja) 2013-02-07
JP6522715B2 (ja) 2019-05-29
EP2476429A4 (en) 2013-02-27
JP2017061511A (ja) 2017-03-30
NZ617397A (en) 2015-02-27
JP2016130261A (ja) 2016-07-21
CN103893746A (zh) 2014-07-02
ES2663322T3 (es) 2018-04-12
JP2019023234A (ja) 2019-02-14
IL217854A0 (en) 2012-03-29
HK1168284A1 (en) 2012-12-28
JP2018024710A (ja) 2018-02-15
JP2017105858A (ja) 2017-06-15
CN102470164B (zh) 2014-04-09
IL217854A (en) 2016-08-31
KR20150021590A (ko) 2015-03-02
JP6275900B2 (ja) 2018-02-07
KR20200115673A (ko) 2020-10-07
JP2017105860A (ja) 2017-06-15
US20120252729A1 (en) 2012-10-04
AU2010293488B2 (en) 2014-11-27
MX335951B (es) 2016-01-04
KR20120067336A (ko) 2012-06-25
JP6274634B2 (ja) 2018-02-07
MX2012002681A (es) 2012-04-19

Similar Documents

Publication Publication Date Title
BR112012003511A2 (pt) agente para o tratamento ou prevenção de osteoporose, preparação de combinação ou kit de tratamento, e, agente para a inibição ou prevenção de fraturas ósseas
BRPI0813352A2 (pt) Composições de fragmento de tecido para o tratamento de incontinência
BRPI0920847A2 (pt) composto, formulação farmacêutica, e, método para o tratamento, prevenção ou retardo na progressão de câncer em um paciente
BRPI0820212A2 (pt) Dispositivo para tratamento de fraturas, método para tratamento de fraturas, e, kit para tratamento de fraturas
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BRPI0907837A2 (pt) Dispositivos médicos para o tratamento de um local-alvo e método associado
BRPI0920111A2 (pt) dispositivo corrediço unidirecional para implantes de fixação intramedulares e intertrocantéricos.
BRPI1015336A2 (pt) composições para tratamento de tecidos que compreendem polímeros de organossiloxano
BR112012018943A8 (pt) medicamento e método para o tratamento e/ou prevenção de um câncer
IL198663A0 (en) Tissue treatment methods
IL207713A0 (en) Formulation and method for the prevention and treatment of bone metastases or other bone diseases
IL231510B (en) Preparations for the treatment of bone diseases and broken bones
EP2303160A4 (en) BONE FRACTURE TREATMENT DEVICES AND METHODS OF USE
BRPI0917189A2 (pt) dispositivo para uso em tratamento cirúrgico de tórax em funil e método de tratamento.
EP2136814A4 (en) MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE
BRPI1009860A2 (pt) composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais
AU324215S (en) Handpiece for massage or therapy
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI1006733A2 (pt) kit para formação de imagem médica marcada e/ou produtos terapêuticos, agente de pré-marcação, sonda de formação de imagem, sonda terapêutica e método
GB2497899B (en) Sanguiin for use in the prevention or treatment of bone marrow inhibition
ZA201303529B (en) Implantable device for preventive or curative treatment of fractures of the femur, associated ancillary device
EP2413837A4 (en) METHODS FOR TREATING MYOFASCIAL, MUSCLE AND / OR BACK PAIN
ZA201007005B (en) Methods of diagnosing, preventing and treating bone mass diseases
BRPI0807730A2 (pt) Método de condicionamento de tecidos e composição sólida para tratamento de tecidos
BR112012000614A2 (pt) métodos e composições para o tratamento de condições médicas relacionadas a tireóide com folatos reduzidos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.